Research programme: cholesterol ester transfer protein inhibitors - Bayer HealthCare Pharmaceuticals
Alternative Names: BAY-194789Latest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator Bayer
- Developer Bayer HealthCare Pharmaceuticals
- Class Small molecules
- Mechanism of Action Cholesterol ester transfer protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Atherosclerosis; Low HDL cholesterol
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Atherosclerosis in Germany (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Low-HDL-cholesterol in Germany (PO)
- 01 Mar 2011 Bayer Schering Pharma is now called Bayer Healthcare Pharmaceuticals